Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors

Both the mutational status and the specific mutation of TP53 (p53) have been shown to impact both tumor prognosis and response to therapies. Molecular profiling of solid tumors is confounded by infiltrating wild‐type cells, since normal DNA can interfere with detection of mutant sequences. Our objective was to identify TP53 mutations in 138 stage I–IV colorectal adenocarcinomas and liver metastases without first enriching for tumor cells by microdissection. To achieve this, we developed a harmonized protocol involving multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) with Universal DNA microarray analysis and endonuclease V/ligase mutation scanning. Sequences were verified using dideoxy sequencing. The harmonized protocol detected all 66 mutations. Dideoxy sequencing detected 41 out of 66 mutations (62%) using automated reading, and 59 out of 66 mutations (89%) with manual reading. Data analysis comparing colon cancer entries in the TP53 database (http://p53.curie.fr) with the results reported in this study showed that distribution of mutations and the mutational events were comparable. Hum Mutat 24:63–75, 2004. © 2004 Wiley‐Liss, Inc.

[1]  F. Barany,et al.  Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array , 2004, Clinical Cancer Research.

[2]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Soussi.  Focus on the p53 gene and cancer: Advances in TP53 mutation research , 2003, Human mutation.

[4]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[5]  Thierry Soussi,et al.  The UMD‐p53 database: New mutations and analysis tools , 2003, Human mutation.

[6]  B. Iacopetta.  TP53 mutation in colorectal cancer , 2003, Human mutation.

[7]  A. Riva,et al.  HER2-positive breast cancer: update on Breast Cancer International Research Group trials. , 2002, Clinical breast cancer.

[8]  Francis Barany,et al.  Single nucleotide polymorphism seeking long term association with complex disease. , 2002, Nucleic acids research.

[9]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[10]  A. Ganguly.  An update on conformation sensitive gel electrophoresis , 2002, Human mutation.

[11]  K. Vousden.  Activation of the p53 tumor suppressor protein. , 2002, Biochimica et biophysica acta.

[12]  F. Barany,et al.  An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue , 2002, Oncogene.

[13]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[14]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[15]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[16]  L. Larsen,et al.  Automated mutation screening using dideoxy fingerprinting and capillary array electrophoresis , 2001, Human mutation.

[17]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[18]  W. Krzyzosiak,et al.  Combined SSCP/duplex analysis by capillary electrophoresis for more efficient mutation detection. , 2001, Nucleic acids research.

[19]  S. Goodman,et al.  Detecting colorectal cancer in stool with the use of multiple genetic targets. , 2001, Journal of the National Cancer Institute.

[20]  B. Iacopetta,et al.  P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Pincus,et al.  Common Conformational Effects of p53 Mutations , 2001, Journal of protein chemistry.

[22]  K. Mitchelson,et al.  Overview: The Application of Capillary Electrophoresis for DNA Polymorphism Analysis , 2001 .

[23]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[24]  M. Stratton,et al.  Rapid detection of DNA sequence variants by conformation-sensitive capillary electrophoresis. , 2000, Genomics.

[25]  S. Nilsson,et al.  PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families , 2000, Human mutation.

[26]  B. Iacopetta,et al.  Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. , 2000, European journal of cancer.

[27]  T. Ørntoft,et al.  Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. , 2000, Clinical chemistry.

[28]  S. Hussain,et al.  p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment , 2000, Annals of the New York Academy of Sciences.

[29]  Eric C. Griffith,et al.  Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. White,et al.  Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. , 2000, Cancer research.

[31]  Francis Barany,et al.  Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2 , 2000, Nature Biotechnology.

[32]  A. Walch,et al.  Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer , 2000, The Journal of pathology.

[33]  C Béroud,et al.  p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.

[34]  B. Kimler,et al.  Breast cancer chemoprevention trials using the fine‐needle aspiration model , 2000, Journal of cellular biochemistry. Supplement.

[35]  F. Barany,et al.  Ligase-based detection of mononucleotide repeat sequences. , 1999, Nucleic acids research.

[36]  N. Gerry,et al.  Universal DNA microarray method for multiplex detection of low abundance point mutations. , 1999, Journal of molecular biology.

[37]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[38]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Fossella.  Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. , 1999, Seminars in oncology.

[40]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[41]  Francis Barany,et al.  Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors , 1999, Oncogene.

[42]  A. Levine,et al.  The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells , 1998, Oncogene.

[43]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[44]  W. Thilly,et al.  Use of denaturing-gradient gel electrophoresis to study chromium-induced point mutations in human cells. , 1994, Environmental health perspectives.

[45]  P. Guldberg,et al.  'Broad-range' DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene. , 1994, Nucleic acids research.

[46]  W. Thilly,et al.  Constant denaturant capillary electrophoresis (CDCE): a high resolution approach to mutational analysis. , 1994, Nucleic acids research.

[47]  Riccardo Fodde,et al.  Mutation detection by denaturing gradient gel electrophoresis (DGGE) , 1994, Human mutation.

[48]  D J Prockop,et al.  Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. D. de Goeij,et al.  K-ras point mutations in routinely processed tissues: non-radioactive screening by single strand conformational polymorphism analysis. , 1993, Journal of clinical pathology.

[50]  M. Ridanpää,et al.  Denaturing gradient gel electrophoresis (DGGE) assay for K-ras and N-ras genes: detection of K-ras point mutations in human lung tumour DNA. , 1993, Human molecular genetics.

[51]  T. Sekiya,et al.  F-SSCP: fluorescence-based polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. , 1992, PCR methods and applications.

[52]  F. Barany,et al.  Cloning, overexpression and nucleotide sequence of a thermostable DNA ligase-encoding gene. , 1991, Gene.

[53]  K. Hayashi,et al.  PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. , 1991, PCR methods and applications.

[54]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[55]  V. Rotter,et al.  Molecular basis for heterogeneity of the human p53 protein , 1986, Molecular and cellular biology.